Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Sections
Personal tools
Log in
 
You are here: Home › Protocols › EDRN Biomarker Reference Lab: Pacific Northwest National Laboratory

EDRN Biomarker Reference Lab: Pacific Northwest National Laboratory

231

No coordinating investigator defined.

Other
Other, Specify

The purpose of this project is to develop antibody microarrays incorporating three major improvements compared to previous antibody microarray platforms, and to produce and disseminate these antibody microarray technologies for the Early Detection Research Network (EDRN) and the research community focusing on early detection, and risk assessment of cancer.


Stage I: A feasibility study – comparing a limited number (5) of available scFv library derived antibodies (in a number of antibody formats such as scFv, Fab and IgG) and commercially available monoclonal antibodies directed at the same cancer-associated antigens on the same slide with appropriate controls. This will involve identification, development, and production, of 20 monoclonal antibody pairs specific for 5 antigens with subsequent utilization demonstrated in a micro ELISA assay. The antibody pairs are represented by one detection antibody and 4 capture antibodies derived as affinity matured subclones directed against the same epitope. The capture antibodies will have affinities ranging from 100 nM to 100 pM. Stage II: Extension of the phase I study to ~50 antigens and controls chosen on the basis of potential as cancer biomarkers. In this stage PNNL will: (a) train selected EDRN investigators in the use of the microarray platform, and (b) print a large number of microarrays (1500 slides) for analytical and clinical validation studies.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement